Rivaroxaban News and Research

RSS

Study explores the effect of COVID-19 on platelet function

A new study posted in the pre-print server bioRxiv* aimed to analyze the impact of COVID-19 on platelet proteome and relate the functional responses of platelets and the formation of platelet-neutrophil aggregate in hospitalized COVID-19 patients.

17 Oct 2022

SARS-CoV-2 infection may be a trigger of myelin oligodendrocyte glycoprotein-associated disorder

A new study reported four cases of Myelin Oligodendrocyte Glycoprotein-Associated Disorder that commenced after SARS-CoV-2 infection.

21 Jun 2022

Low-dose apixaban treatment reduces recurrence of venous thromboembolism compared to anticoagulant discontinuation after negative D-dimer

Patients who have suffered from a first episode of unprovoked venous thromboembolism (VTE) have an eight times higher risk of recurrence if they stop treatment after repeated negative D-dimer tests, instead of continuing with low-dose anticoagulant (apixaban).

20 May 2022

Many treatments for intracerebral hemorrhage are not as effective as previously thought, guideline suggests

Some treatments or preventive therapies used to manage intracerebral hemorrhages (ICH), or a bleeding stroke, are not as effective as previously believed, according to the new American Heart Association/American Stroke Association guideline for caring for people with spontaneous ICH, published today in the Association's Stroke journal.

17 May 2022

Reduced kidney function caused by antithrombotic therapy can influence bleeding events

Antithrombotic therapy is prescribed to prevent thrombotic (blood clotting inside a blood vessel) events but the treatment also increases the likelihood of experiencing a bleeding event, which can be extremely serious if it occurs in a vital organ.

25 Mar 2022

Meta-analysis finds intensified anticoagulation had no effect on short term mortality among hospitalized COVID-19 patients

A recent systematic review and meta-analysis evaluated the safety and efficacy of intensified anticoagulation therapy in COVID-19 patients.

11 Mar 2022

Impact of atrial fibrillation in COVID-19 vaccine-induced pericarditis patients

In a new study, a team of researchers described the case of a healthy 49-year old male patient with new-onset atrial fibrillation after receiving the second dose of the COVID-19 mRNA-1273 (Moderna) vaccine.

19 Jan 2022

Trial tests effectiveness of two prospective stroke therapies over standard of care

Another goal of the study is to screen all participants for a mutation known to prevent clopidogrel, a prodrug, from being fully metabolized into its active form.

2 Sep 2021

Study elucidates the use of anticoagulants to treat bleeding in patients with gastrointestinal cancers

A study by Mayo Clinic researchers provides some clarity in the use of direct oral anticoagulants (DOAC), such as apixaban and rivaroxaban, to treat acute venous thromboembolism (VTE) in patients with gastrointestinal cancers.

5 Jun 2021

Rivaroxaban reduces the occurrence of severe ischemic events in patients with peripheral artery disease

Rivaroxaban, in addition to low-dose aspirin, significantly reduced the occurrence of total severe events of the heart, limb or brain and issues related to other vascular complications in patients with symptomatic peripheral artery disease (PAD) who underwent lower extremity revascularization, a procedure to open blocked arteries in the leg.

17 May 2021

Study shows adverse outcomes associated with use of more blood thinners

More blood thinners aren't automatically better, another study confirms. A new publication in JAMA Internal Medicine focuses on the minimal pros and the concerning cons of combining a daily aspirin with a drug from the newer class of anticoagulants that include apixaban, dabigatran, edoxaban and rivaroxaban.

19 Apr 2021

Dual-pathway approach can lead to better outcomes in patients with heart stents

Pairing a blood-thinning drug with aspirin daily for patients who have an angioplasty with a stent can contribute to better health outcomes, including lower risk of death, than aspirin alone, according to a recent study by cardiologists at the University of Alberta and Mazankowski Alberta Heart Institute.

28 May 2020

Study provides indications and techniques of lower extremity revascularization

Lower extremity artery disease is a leading cause of morbidity and mortality worldwide, affecting hundreds of millions of people.

7 May 2020

Clopidogrel added to aspirin and rvaroxaban shows no additional benefit for peripheral artery disease

The results of VOYAGER PAD found that people with peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing lower extremity revascularization--a procedure to treat blocked arteries in the leg--had a significant reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone.

31 Mar 2020

Direct oral anticoagulant more effective in lowering risk of VTE after common orthopedic surgeries

The direct oral anticoagulant rivaroxaban dramatically cut the likelihood of serious venous thromboembolism (VTE) in people recovering from lower limb orthopedic surgery requiring immobilization in comparison with enoxaparin, another anticoagulant agent, according to research presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.

30 Mar 2020

Oral apixaban as effective as dalteparin for treating blood clots in people with cancer

For people with cancer, the oral blood thinner apixaban is at least as effective as dalteparin, a low molecular weight heparin given by injection, in preventing a repeat venous thromboembolism (VTE), or blood clot, with no excess in major bleeding events, according to Phase 3 trial results presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.

30 Mar 2020

Low-dose rivaroxaban reduces adverse heart events in symptomatic PAD post-intervention

People with symptomatic peripheral artery disease who took the blood thinner rivaroxaban with aspirin after undergoing a procedure to treat blocked arteries in the leg (lower extremity revascularization) had a 15% reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone, according to research presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.

30 Mar 2020

New research provides welcomed news for countless patients taking PPIs

For patients taking proton pump inhibitors to treat gastroesophageal disease (GERD) or other acid-related conditions, new research puts safety concerns to rest.

7 Jun 2019

Using blood thinners in heart failure patients associated with reduced risk of thromboembolic events

Researchers at University of California San Diego School of Medicine found that using blood thinners in patients with worsening heart failure, coronary artery disease or irregular heart rhythms was associated with a 17 percent reduced risk of thromboembolic events, such as stroke and heart attack.

25 Apr 2019

Drug that reverses blood thinning effects stops acute life-threatening bleeding

A drug that reverses the blood thinning effects of factor Xa inhibitors effectively stopped acute life-threatening bleeding in patients taking a factor Xa inhibitor blood thinner drug, according to late breaking science presented at the American Stroke Association's International Stroke Conference 2019, a world premier meeting for researchers and clinicians dedicated to the science and treatment of cerebrovascular disease.

8 Feb 2019

Rivaroxaban News and Research

Study explores the effect of COVID-19 on platelet function

SARS-CoV-2 infection may be a trigger of myelin oligodendrocyte glycoprotein-associated disorder

Low-dose apixaban treatment reduces recurrence of venous thromboembolism compared to anticoagulant discontinuation after negative D-dimer

Many treatments for intracerebral hemorrhage are not as effective as previously thought, guideline suggests

Reduced kidney function caused by antithrombotic therapy can influence bleeding events

Meta-analysis finds intensified anticoagulation had no effect on short term mortality among hospitalized COVID-19 patients

Impact of atrial fibrillation in COVID-19 vaccine-induced pericarditis patients

Trial tests effectiveness of two prospective stroke therapies over standard of care

Study elucidates the use of anticoagulants to treat bleeding in patients with gastrointestinal cancers

Rivaroxaban reduces the occurrence of severe ischemic events in patients with peripheral artery disease

Study shows adverse outcomes associated with use of more blood thinners

Dual-pathway approach can lead to better outcomes in patients with heart stents

Study provides indications and techniques of lower extremity revascularization

Clopidogrel added to aspirin and rvaroxaban shows no additional benefit for peripheral artery disease

Direct oral anticoagulant more effective in lowering risk of VTE after common orthopedic surgeries

Oral apixaban as effective as dalteparin for treating blood clots in people with cancer

Low-dose rivaroxaban reduces adverse heart events in symptomatic PAD post-intervention

New research provides welcomed news for countless patients taking PPIs

Using blood thinners in heart failure patients associated with reduced risk of thromboembolic events

Drug that reverses blood thinning effects stops acute life-threatening bleeding

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News